Brussels - Brussels Delayed Price. Currency in EUR


Allée de la Recherche, 60
Brussels 1070
32 2 559 99 99

Full Time Employees7,478

Key Executives

NameTitlePayExercisedYear Born
Mr. Jean-Christophe TellierChief Exec. Officer and Exec. Director3.07MN/A1959
Mr. Detlef ThielgenChief Financial Officer and Exec. VPN/AN/A1960
Ms. Anna S. RichoExec. VP and Gen. CounselN/AN/A1960
Dr. Bharat TewarieChief Marketing Officer and Exec. VPN/AN/A1961
Prof. Iris Löw-FriedrichChief Medical Officer, Head of Devel. & Medical Patient Value Practices and Exec. VPN/AN/A1960
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.


UCB SA, a biopharmaceutical company, focuses on the discovery and development of medicines and solutions for people living with severe diseases of the immune system or of the central nervous system. Its core products include Cimzia for rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis, ankylosing spondylitis, and Crohn's disease; Vimpat, Keppra, and Briviact for epilepsy; and Neupro for Parkinson's disease and restless legs syndrome. The company also offers Zyrtec and Xyzal for allergy. Its product pipeline includes Evenity for the treatment of osteoporosis; bimekizumab for psoriasis, psoriatic arthritis, and ankylosing spondylitis diseases; dapirolizumab pegol for systemic lupus erythematosus; padsevonil for highly drug resistant epilepsy; seletalisib for Sjögren's syndrome; rozanolixizumab for immune thrombocytopenia; UCB4144/VR942 for asthma; UCB6673, UCB7858, and UCB0159 for the treatment of neurology; and UCB3491 and UCB0599 for bone treatment. UCB SA was founded in 1928 and is based in Brussels, Belgium.

Corporate Governance

UCB SA’s ISS Governance QualityScore as of March 1, 2018 is 5. The pillar scores are Audit: 1; Board: 4; Shareholder Rights: 7; Compensation: 5.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.